Medscape
The US Food and Drug Administration (FDA) has expanded approval for fingolimod (Gilenya, Novartis) to the treatment of children and adolescents with relapsing multiple sclerosis (MS) who are aged 10 years or older, the first such approval of a drug to
FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patientsFDA.gov
FDA approves first drug to treat MS in childrenHealio
Fingolimod OK’d for Pediatric MSMedPage Today
Business Insider
all 12 news articles …read more

Source: HEALTH